A class action lawsuit has been filed against Capricor Therapeutics, Inc. on behalf of investors who purchased or otherwise acquired the company’s securities during the period from Dec. 17, 2025, through July 26, 2026. The complaint alleges that FDA (U.S. drug regulator) briefing documents released before the market opened on July 27, 2026, ahead of an AdCom (FDA advisory committee) meeting on Capricor’s resubmitted Dermamiocel Biologics License Application, raised concerns about changes to the pre-specified statistical analysis plan. The complaint says the final plan was not submitted to the FDA for review before the application was filed and was not discussed or agreed upon. Capricor shares fell $12.70, or 64%, to close at $7 on July 27. Investors with losses may contact Kaplan Fox & Kilsheimer LLP, although they do not need to seek lead-plaintiff status to participate in any potential recovery. The deadline to move the court for appointment as lead plaintiff is Sept. 28, 2026.